Ultimate Cardiology education center for researchers
Statins Evaluation in Coronary Procedures and Revascularization

Patients presenting with ACS were randomized in a 1:1 fashion to receive either two loading doses of atorvastatin 80 mg before and 24 hours after a planned early invasive approach (n = 2,087) or placebo (n = 2,104). All patients in both groups were to receive 40 mg/d of atorvastatin after the procedure through 30 days.
 
Total number of enrollees: 4,191
Duration of follow-up: 30 days
Mean patient age: 61.8 years
Percentage female: 26%
Inclusion criteria:
 
Age ≥18 years
ACS with planned invasive management planned within 7 days
Exclusion criteria:
 
Use of fibrate in 24 hours prior to loading dose
Use of any statin at maximum dose in the 24 hours prior to loading dose
Other salient features/characteristics:
 
ST-segment elevation myocardial infarction (STEMI): 25%, NSTEMI: 60%, unstable angina: 15%
Previous long-term statin use: 29%
Diabetes: 32%
Initial treatment strategy: percutaneous coronary intervention (PCI) 65%, coronary artery bypass grafting (CABG) 8%, medical management 27%